Tiny Health Is Now Available on Fullscript

Fullscript is committed to supporting providers in delivering comprehensive, whole person care, which means continually expanding access to diagnostics that generate clinically actionable data. We're pleased to announce a new step forward on that front: Tiny Health has officially joined the Fullscript labs catalog.

With Tiny Health testing now available, providers can order advanced microbiome diagnostics alongside patient supplement plans, bringing diagnostics and intervention planning together into a single, streamlined workflow.

Who is Tiny Health?

Tiny Health is a microbiome diagnostics company offering at-home testing of the gut and vaginal microbiomes across the lifespan, from pregnancy and infancy through adulthood. 

Testing is performed using shotgun metagenomic sequencing, which profiles over 120,000 microorganisms, including bacteria, fungi, viruses, archaea, and parasites, at strain-level resolution. Reports pair this compositional data with evidence-based nutrition and lifestyle recommendations intended to support clinical decision-making.

How Tiny Health supports clinical practice

Adding Tiny Health to the Fullscript labs catalog allows providers to order, track, and interpret these diagnostics directly within the Fullscript platform.

Tiny Health's testing is built for providers who require strain-level microbial resolution rather than surface-level or presence/absence markers. Assessments are designed to surface root causes of digestive, immune, metabolic, and hormonal presentations, supporting a more targeted, evidence-informed approach to care.

Key clinical differentiators of Tiny Health

Shotgun metagenomic sequencing over standard methods

Tiny Health uses shotgun metagenomic sequencing to detect bacteria, fungi, viruses, archaea, and parasites at the strain level, along with the functional genes those organisms carry.

Functional gene capacity insights

Because shotgun sequencing captures the full genetic content of a sample rather than a single marker gene, Tiny Health can report on the microbiome's metabolic and functional capacity, not just which organisms are present. 

Reports assess gene-level pathways tied to specific physiological processes, including the capacity for neuroactive metabolite production (such as GABA synthesis via gadA/gadB and GABA degradation via gabT/puuE), short-chain fatty acid production, mucus degradation, hydrogen sulfide production, and lipopolysaccharide (LPS) biosynthesis. This distinction matters clinically: a taxon's presence does not confirm that it is actively expressing a given function, since gene carriage is condition-dependent and strain-specific. 

Reporting at the functional gene level allows providers to assess whether the microbiome has the genetic capacity to drive a given pathway, offering a mechanistic bridge between composition and downstream physiological effect, and a more actionable data point than taxonomy alone.

Tiered testing options

The Gut Health Test provides microbiome genetic data, including strain-level organism identification and functional gene capacity, generated through shotgun metagenomic sequencing. 

The Pro Gut Health Test builds on the same genetic dataset and adds a comprehensive non-microbial stool chemistry panel, providing practitioners with a mechanistic layer of data beyond organism identification alone. 

The Pro Gut Health Test includes:

• Elastase
• Fat stain
• Carbohydrates
• Secretory IgA
• Butyrate
• Acetate
• Propionate
• Valerate
• Lactoferrin
• Lysozyme
• Calprotectin
• pH
• Beta-glucuronidase
• Occult blood

Together, these markers assess digestion and absorption, immune activity, fermentative and metabolic function, inflammation, and overall intestinal health, supporting a more complete clinical picture than compositional data alone.

Dual gut and vaginal microbiome testing

Tiny Health is among a small number of laboratories offering both gut and vaginal microbiome panels, allowing providers to evaluate microbial health across multiple body systems within a single diagnostic relationship.

Early-life microbiome specialization

Testing and interpretive frameworks are validated for infants and children, with age-specific reference ranges and clinical guidance, supporting pediatric and family medicine providers focused on early intervention.

Individualized, evidence-based recommendations

Reports translate raw sequencing data into nutrition, lifestyle, and supplement guidance specific to each patient's microbiome profile, supporting direct clinical application.

Condition associations

Reports map specific microbiome findings, at both the organism and functional gene level, to associations with clinical conditions supported in the research literature, including digestive, immune, metabolic, endocrine, and dermatologic presentations. 

Rather than requiring providers to research the clinical significance of each finding independently, this feature surfaces relevant condition-level context directly within the report, helping providers connect compositional and functional data to a patient's presenting symptoms more efficiently.

Built-in longitudinal tracking

Testing supports repeat assessment over time, allowing providers to monitor microbiome shifts and evaluate the impact of dietary, probiotic, or lifestyle interventions against a patient's own baseline.

Access Tiny Health testing through Fullscript

The addition of Tiny Health expands Fullscript's specialty lab catalog, giving providers a broader set of diagnostic partners to draw on when personalizing care.

Providers already registered for labs on Fullscript can begin ordering Tiny Health testing immediately. Providers who are not yet registered can do so below to begin accessing Tiny Health diagnostics through the Fullscript platform.